Recombinant Proteins
Recombinant proteins are sequence-defined biologics produced by expression systems (bacterial, yeast, mammalian or cell-free) for therapeutics, vaccine antigens, diagnostics, and research reagents. Rapid, scalable production and formulation for stability and cold-chain independence are essential for military and austere clinical settings.
Technical Challenges
Manufacturing speed and surge capacity for emergent threats (pandemics, biothreats).
Stability and formulation for extreme temperatures and prolonged field storage.
Purity and endotoxin removal for rapid therapeutic deployment in austere conditions.
Scale-down, portable manufacturing compatible with GMP-like quality in forward settings.
Protein aggregation, proteolytic degradation, and cold-chain dependence limiting field use.
Emerging Opportunities
On-demand, validated small-footprint production platforms with rapid changeover.
Lyophilized or thermo-stable recombinant therapeutics and diagnostics requiring minimal reconstitution.
Rapid, field-deployable QC assays for potency, identity, and contamination.
Standardized rapid downstream purification workflows that preserve activity and reduce time-to-dose.
Integrated supply-chain solutions for raw materials, single-use consumables, and platform interoperability.
Current and Emerging Technologies in Recombinant Proteins
Expression platforms
E. coli, yeast (Pichia), insect and CHO cells remain standard for different protein classes; platform choice balances yield, post-translational modifications, and speed.
Cell-free protein synthesis
On-demand, decentralizable production with rapid turnaround, reduced biosafety containment, and suitability for austere or forward-deployed manufacturing.
Continuous and single-use bioprocessing
Continuous capture chromatography, single-use upstream bioreactors, and modular downstream units reduce footprint, cross-contamination risk, and time to product.
Stabilization and formulation science
Lyophilization, excipient engineering, nanoparticle encapsulation, and thermostable formulation techniques reduce cold-chain dependence for field use.
Analytical and rapid QC tools
Point-of-use potency assays, rapid endotoxin tests, and compact spectrometric tools enable batch release and safety checks near the point of care.
Importance to Military Medicine
Combat casualty care and trauma
Recombinant clotting factors, growth factors, and antimicrobial peptides can reduce hemorrhage, infection, and accelerate tissue repair in polytrauma and blast injuries.
Prolonged and distributed care
Thermostable biologics and on-demand production extend advanced therapeutics to far-forward units where evacuation is delayed.
Biodefense and outbreak response
Rapid manufacture of antigens, neutralizing proteins, and diagnostic reagents strengthens readiness against emergent pathogens and AMR threats.
Supply resilience and readiness
Modular platforms and distributed manufacturing reduce dependence on centralized supply chains during conflict or disruptions.
Alignment with the MTEC Mission
Accelerates transition of biologics from research to field-ready products aligned with MTEC's mission to deliver military-relevant medical technologies faster.
Supports DoD priorities in biodefense, force health protection, and prolonged care by creating deployable manufacturing and stable formulations.
Enables dual-use innovations that benefit civilian health systems while meeting military specifications for ruggedness, speed, and scalability.
Dual-Use (Military + Civilian) Applications
Therapeutics: recombinant clotting factors, enzymatic wound debridement agents, and monoclonal antibody fragments for infection control.
Vaccines & prophylactics: rapid antigen production for emergent pathogens and adjuvant proteins optimized for stability.
Diagnostics & reagents: high-quality antigens, controls, and affinity reagents for point-of-care tests and laboratory assays.
Research and regenerative medicine: growth factors, cytokines, and engineered proteins to support tissue repair, nerve regeneration, and rehabilitation.
Explore MTEC Members with Recombinant Proteins Capabilities
MTEC members bring interdisciplinary strengths — process chemistry, GMP manufacturing, formulation science, and military clinical experience — enabling end-to-end development from design to field validation.
Academic partners contribute discovery and directed-evolution expertise; industry provides scale-up and regulatory pathways; military clinical sites enable realistic testing in austere and prolonged-care scenarios.
Explore member profiles to identify capabilities in cell-free systems, single-use GMP workflows, stabilization chemistry, and rapid QC tools that accelerate military-relevant recombinant protein solutions.
101 Members with Recombinant Proteins capabilities.
The Advanced Regenerative Manufacturing Institute (ARMI) is a member-based, nonprofit organization dedicated to advancing the bioeconomy of the United States. Its mission encompasses enhancing manufacturing, healthcare, and education and workforce development, aiming to create a scalable and effective manufacturing ecosystem for engineered cells, tissues, and organs.
Georgia Southern University is a vibrant institution with over 26,100 students across three campuses in Statesboro, Savannah, and Hinesville. The university offers 132 degree programs at the associate, bachelor’s, master’s, and doctorate levels, emphasizing student success, community impact, and research excellence. With a commitment to inclusivity and engagement, Georgia Southern fosters a supportive environment for diverse learners, including military-affiliated and adult students. The university is dedicated to transforming lives through education and community engagement, aligning its programs with regional needs. Additionally, Georgia Southern provides accelerated pathways for students to fast-track their master's degrees, enhancing educational opportunities. The university also emphasizes career readiness and public impact research, preparing students for successful careers and contributing to community development.
Nuclera develops automated benchtop platforms and integrated systems for rapid protein expression, optimization, and purification, utilizing cell-free synthesis, digital microfluidics, and software-driven workflows. Their technology enables miniaturized and scalable protein prototyping—including challenging targets such as membrane proteins—directly at the lab bench. Nuclera serves academic and industrial researchers, focusing on reducing turnaround time for functional protein access and streamlining screening and production. The company has secured significant funding to enable broad commercialization, expanded their leadership team to support scale-up, and continues to drive advancements in drug discovery, proteomics, and experimental automation.
VirTech Bio is an early-stage biotechnology company based in Natick, Massachusetts, focused on developing a human-derived hemoglobin-based oxygen carrier (HBOC) for use as a temporary blood substitute in trauma and transplantation. The company leverages expertise in hemoglobin polymerization to address critical needs in emergency medicine and organ preservation, with a pipeline also targeting veterinary and research applications. Process innovations allow scalable and contract-based manufacturing, supported by significant non-dilutive funding from the US Department of Defense and private investment.
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to developing pathogen-specific bacteriophage therapeutics to combat antibiotic-resistant and difficult-to-treat bacterial infections. With a focus on addressing the global antibiotic resistance crisis, Armata leverages its proprietary bacteriophage-based technology to develop high-impact, best-in-class phage therapeutics. The company operates from a 56,000 square foot facility in Los Angeles, California, equipped for phage product development from bench to clinic. Armata's team of microbiologists and scientists work on discovering natural phages and enhancing them through synthetic biology and engineering to create tailored drug products for clinical trials.
Anavatos Bio is an early-stage biotechnology start-up based in Seattle, Washington, dedicated to revolutionizing biologics manufacturing. The company is driven by a team of experienced scientists, engineers, and entrepreneurs passionate about increasing access to protein therapeutics. Their mission is to enable faster, more efficient, and cost-effective production of biologics at smaller scales, supporting early-phase research and advancing a new medical paradigm that delivers greater value to patients.
Auburn University Research & Economic Development is dedicated to advancing research and economic growth through a collaborative effort among its various colleges and departments. The organization focuses on fostering innovation, supporting faculty and student research, and facilitating partnerships with industry and government to address societal challenges and enhance the quality of life. Recent initiatives include the launch of the Team Science Series to promote interdisciplinary collaboration and the development of the Gulf Coast Engineering Research Station to address coastal environmental challenges.
Seek Labs is a biotechnology company headquartered in Salt Lake City, Utah, dedicated to advancing scientific discovery and delivering universal healthcare solutions. The company specializes in next-generation point-of-care molecular diagnostics and programmable CRISPR-based therapeutics, aiming to bridge the gap between disease outbreak and intervention. Powered by its proprietary AI discovery engine, BioSeeker™, Seek Labs is building a modular, full-stack system that enables rapid response to emerging pathogens, scalable precision treatments, and accessible diagnostics. The company is committed to global health innovation, sustainability, and community engagement, and is a proud member of Utah's BioHive life sciences ecosystem. Seek Labs' mission is to empower individuals with healthcare solutions tailored to their specific needs, revolutionizing the detection and treatment of diseases for both human and animal health.
The Institute for Integrative & Innovative Research (I3R) at the University of Arkansas is dedicated to pioneering solutions to complex societal challenges through convergence research. With a mission to advance research excellence and stimulate economic development, I3R focuses on deploying innovations at scale through collaboration across various sectors, including academia, industry, and government.
ATCC is a nonprofit biological resource center, with a nearly century-long legacy supporting public health, biodefense, and global health security. ATCC provides critical infrastructure for infectious disease research and CBR threat response. Our biorepository operations support federal agencies, academia, and industry through secure specimen handling, reagent authentication, and global distribution. ATCC manages over 22 million vials under federal contracts, including repositories for NIAID, CDC, BARDA, NCI, FDA, and USDA. These programs enable rapid deployment of validated biological materials for vaccine development, diagnostic assay verification, and therapeutic screening against high-consequence pathogens such as SARS-CoV-2. Certified under ISO 9001, 13485, 17025, and 17034, ATCC ensures quality, traceability, and regulatory compliance across its operations. Our high-containment laboratories (BSL-2 and BSL-3, with access to BSL-4 through partners) and Select Agent license position us to support MTEC-aligned efforts in emerging infectious diseases and medical countermeasure development for CBRN threats.
The University of Chicago is a prestigious urban research university committed to rigorous inquiry and intellectual freedom. Founded in 1890, it has produced numerous Nobel laureates and is known for its transformative education and groundbreaking research across various fields. The university fosters an inclusive and diverse learning environment, encouraging participation from all community members.
Boston University is a major research institution committed to leading breakthroughs across various disciplines. The Office of Research supports and advances research excellence, fostering collaboration among researchers, industry partners, and government leaders to address significant societal challenges.
Sunflower Therapeutics is a women-owned and led biotechnology public benefit corporation founded in 2018, dedicated to democratizing access to protein manufacturing worldwide. The company develops next-generation, automated, and fully-integrated protein manufacturing solutions that simplify the process from discovery to full-scale biomanufacturing. Their mission is to make high-quality, cost-effective therapeutics, vaccines, and protein-based products accessible globally, especially in low- and middle-income countries, by leveraging innovative technologies, sustainable practices, and intuitive equipment. Sunflower’s vision is to transform the global health landscape by enabling more medicines and protein products to reach patients and consumers everywhere. Their core technologies include efficient microbial hosts, data-driven process development, and modular manufacturing facilities, supporting agile, rapid, and cost-effective production cycles for a wide range of protein-based products.
Baylor University is a preeminent Christian research university committed to addressing the world's most meaningful challenges through top-tier research and scholarship. Recognized as an R1 research institution, Baylor focuses on infusing its distinct Christian mission into its research initiatives, fostering a commitment to excellence and innovation.
IntegerBio is at the forefront of Immunovirology, committed to combating serious viral diseases by pioneering the intersection of immunology and virology. The company focuses on developing broad multi-viral therapeutics using cutting-edge biology and data-focused approaches. Their mission is to harness the power of science to design therapeutics with durable responses across multiple viruses, aiming for a future without the fear of viral disease.
Base Pair Biotechnologies specializes in custom aptamer discovery and development for research, diagnostics, therapeutics, and industrial applications. The company leverages proprietary multiplex selection, advanced bioinformatics, and chemical modification techniques to develop high-affinity and selective nucleic acid aptamers. Base Pair enables affinity reagent development, biosensor design, and molecular detection for a broad range of targets and partners across academia and industry.

Arizona State University
ASU Crosscutting Technologies to Enhance Military Medical Readiness and Resilience
Dr. Rachel Cassalia leads MTEC-supported efforts at ASU to shift military health from reactive care to proactive readiness through data-driven prevention.
University of Pittsburgh
Topical Metformin Lotion for Tendinopathy Prevention
University of Pittsburgh study shows topical metformin prevents overuse tendon injury. This work was sponsored through MTEC project 22-02-MPAI-014.
Theradaptive
Theradaptive’s RESTORE Trial Initiation for OsteoAdapt™ DE
Theradaptive launches RESTORE Phase I/II trial of OsteoAdapt™ DE for faster, precision bone healing in craniofacial injuries. MTEC-funded study targets improved recovery for military and civilian patients.
Altec
Autonomous Rehabilitation Device for Improved Recovery in Warfighters
The OSCIR platform—developed by Altec Inc in collaboration with the Naval Health Research Center—is bringing clinical-grade, real-time movement analysis to the front lines. Funded under MTEC-22-02-MPAI